Oncologist preferences for health states associated with the treatment of advanced ovarian cancer

Lisa Hess (), Daniel Malone, Grant Skrepnek, Pamela Reed, Edward Armstrong and Stephen Coons

Applied Health Economics and Health Policy, 2010, vol. 8, issue 4, 217-223

Abstract: These data suggest that oncologists may choose treatments that maximize clinical efficacy only when not associated with severe toxicities or low emotional well-being unless associated with a large improvement in efficacy. Physicians may prefer a more toxic chemotherapy regimen that improves survival, and are more willing to compromise emotional well-being for a large survival advantage in the setting of newly diagnosed disease. Slight improvements in clinical efficacy may not be acceptable to oncologists unless associated with higher emotional well-being for the patient. Copyright Adis Data Information BV 2010

Date: 2010
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/11317510-000000000-00000 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:8:y:2010:i:4:p:217-223

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.2165/11317510-000000000-00000

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().